高免赔额健康保险对糖尿病微血管病变诊疗的影响
该队列研究比较了雇主强制转换保险计划前后糖尿病患者微血管病变相关诊疗的延迟情况。研究组为50,790例连续参加低免赔额计划后转为高免赔额计划的糖尿病患者,对照组为335,178例同期低免赔额计划患者。结果显示高免赔额计划与视网膜病变筛查延迟0.7个月、严重视网膜病变诊断延迟2.9个月、视力丧失诊疗延迟3.8个月相关,而肾病相关指标无显著变化。
要点
- 高免赔额保险与视网膜病变筛查延迟0.7个月相关。
- 严重视网膜病变诊断延迟2.9个月,视力丧失诊疗延迟3.8个月。
- 肾病相关指标在高免赔额与低免赔额组间无显著差异。
核心结论
- 高免赔额健康保险参保的糖尿病患者相比低免赔额参保者,视网膜病变诊断和视力丧失诊疗延迟可达3.8个月。
研究设计与样本
- 队列研究,使用大型全国商业(及Medicare Advantage)保险理赔数据集,比较保险设计变更前后的匹配组。
- 研究组为50,790例糖尿病患者,基线年连续参加低免赔额(≤$500)计划,后经雇主强制转换至高免赔额(≥$1,000)计划并随访最多4年。
- 对照组为335,178例糖尿病患者,同期参加低免赔额计划。
主要发现
- 高免赔额计划 enrollment 与视网膜病变筛查相对延迟0.7个月(95% CI 0.4, 1.0)相关。
- 高免赔额计划与严重视网膜病变诊断延迟2.9个月(95% CI 0.5, 5.3)相关。
- 高免赔额计划与视力丧失诊断/治疗延迟3.8个月(95% CI 1.2, 6.3)相关。
- 随访期间,高免赔额组成员肾病相关指标相对对照组无统计学显著变化。
关键数值与推荐
- 高免赔额计划对肾病筛查自付费用低,但对视网膜病变筛查无低自付费用。
- 低免赔额定义为≤$500,高免赔额定义为≥$1,000。
临床怎么用
- 临床医生应关注高免赔额保险糖尿病患者视网膜病变筛查和视力诊疗的潜在延迟。
- 对高免赔额保险患者,可主动提醒并协助安排视网膜病变筛查以减少延迟。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Affordable Care Act mandates that primary preventive services have no out-of-pocket costs but does not exempt secondary prevention from out-of-pocket costs. Most commercially insured patients with diabetes have high-deductible health plans (HDHPs) that subject key microvascular disease-related services to high out-of-pocket costs. Brief treatment delays can significantly worsen microvascular disease outcomes. RESEARCH DESIGN AND METHODS: This cohort study used a large national commercial (and Medicare Advantage) health insurance claims data set to examine matched groups before and after an insurance design change. The study group included 50,790 patients with diabetes who were continuously enrolled in low-deductible (≤$500) health plans during a baseline year, followed by up to 4 years in high-deductible (≥$1,000) plans after an employer-mandated switch. HDHPs had low out-of-pocket costs for nephropathy screening but not retinopathy screening. A matched control group included 335,178 patients with diabetes who were contemporaneously enrolled in low-deductible plans. Measures included time to first detected microvascular disease screening, severe microvascular disease diagnosis, vision loss diagnosis/treatment, and renal function loss diagnosis/treatment. RESULTS: HDHP enrollment was associated with relative delays in retinopathy screening (0.7 months [95% CI 0.4, 1.0]), severe retinopathy diagnosis (2.9 months [0.5, 5.3]), and vision loss diagnosis/treatment (3.8 months [1.2, 6.3]). Nephropathy-associated measures did not change to a statistically significant degree among HDHP members relative to control subjects at follow-up. CONCLUSIONS: People with diabetes in HDHPs experienced delayed retinopathy diagnosis and vision loss diagnosis/treatment of up to 3.8 months compared with low-deductible plan enrollees. Findings raise concerns about visual health among HDHP members and call attention to discrepancies in Affordable Care Act cost sharing exemptions.
引用
- Wharam JF, Wallace J, Argetsinger S, et al. Diabetes Microvascular Disease Diagnosis and Treatment After High-Deductible Health Plan Enrollment. Diabetes Care. 2022. PMID: 34588211. doi:10.2337/dc21-0407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。